Literature DB >> 9531330

Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course.

L Amiot1, M Onno, T Lamy, C Dauriac, P Y Le Prise, R Fauchet, B Drenou.   

Abstract

Major histocompatibility complex class I molecule expression is reduced in some malignant tumours permitting escape from immune surveillance and is therefore associated with a poor prognosis. Seven cases of non-Hodgkin lymphomas out of 300 cases of malignant lymphoproliferative disorders totally lacked expression of class I molecules as determined by flow cytometry. Clinical data confirmed a particular aggressiveness of these cases with frequent extra-nodal involvement, a poor international prognostic index, a histological high grade and a poor outcome leading to early death in five of the seven cases. A previous diagnosis of follicular lymphoma characterized by bcl-2 rearrangements was made in four of these cases. HLA-G (class Ib gene), which is reported to bind killer inhibitory receptors on NK cells, was absent from the cell surface. However, it was detected in three out of four cases at the mRNA level with transcripts encoding soluble forms. Additional analysis revealed other abnormalities: class II was negative in four out of the seven NHL cases and decreased expression of beta2 microglobulin was observed in all cases. Peptide transporter proteins (TAP1) were detected in various degrees by immunocytochemistry. These observations showed that total lack of class I or class II molecules is a rare event in NHL and is associated with a poor prognosis. This could support a role for specific autologous T cells in immune surveillance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531330     DOI: 10.1046/j.1365-2141.1998.00631.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  14 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.

Authors:  Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

Review 3.  Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia.

Authors:  Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

4.  T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.

Authors:  Tamara Hilmenyuk; Carla A Ruckstuhl; Michael Hayoz; Christian Berchtold; Jean-Marc Nuoffer; Shyam Solanki; Hector C Keun; Paul A Beavis; Carsten Riether; Adrian F Ochsenbein
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

5.  Thymic epithelial tumors can develop along two different pathogenetic pathways.

Authors:  R Zhou; A Zettl; P Ströbel; K Wagner; H K Müller-Hermelink; S Zhang; A Marx; P Starostik
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma.

Authors:  Mojun Zhao; Frederick L Flynt; Mei Hong; Han Chen; Carolyn A Gilbert; Nicole T Briley; Sophia C Bolick; Kenneth L Wright; Janet F Piskurich
Journal:  Mol Immunol       Date:  2007-02-14       Impact factor: 4.407

7.  Differential diagnostic significance of the paucity of HLA-I antigens on metastatic breast carcinoma cells in effusions.

Authors:  E Magyarosy; W J Martin; E W Chu; S E Martin
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

8.  Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas.

Authors:  Marie Tosolini; Christelle Algans; Frédéric Pont; Bernard Ycart; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

Review 9.  Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice?

Authors:  Leonidas Alevizos; Ilias P Gomatos; Spyridon Smparounis; Manousos M Konstadoulakis; Georgios Zografos
Journal:  Can J Surg       Date:  2012-04       Impact factor: 2.089

10.  The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells.

Authors:  Kelly A Cycon; James L Clements; Renae Holtz; Hiroshi Fuji; Shawn P Murphy
Journal:  Immunology       Date:  2009-01-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.